EGFR and non-small cell lung carcinoma: It was the first approved targeted medicine for adult patients with locally advanced or metastatic NSCLC progressing on or after EGFR TKI therapy and patients with metastatic EGFR-mutant and acquired EGFR T790M mutation (Mok et al., 2017; Soria et al., 2018).